Biotechnology News and Research

RSS

New ELISA protocol for Midkine detection in blood serum

BioGenes GmbH, a supplier of GMP compliant immunoassay and antibody services, has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum.

16 Nov 2010

BiovaxID lymphoma vaccine to be featured at ASH Meeting

Biovest International, Inc. today announced that BiovaxID, Biovest's personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.

16 Nov 2010

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

Dyadic third quarter total revenue decreases to $2.0 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

GenturaDx will display its proprietary molecular diagnostic system, the IDbox System, at the annual meeting of the Association for Molecular Pathology (AMP) in San Jose, Calif. on November 17 – 20, 2010. The IDbox System incorporates all aspects of its proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette.

15 Nov 2010

PAREXEL wins 2010 Scrip Award for 'Clinical Research Team of the Year'

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has won the 2010 Scrip Award for "Clinical Research Team of the Year." The award was presented to PAREXEL at the sixth annual Scrip Awards ceremony, hosted by Scrip Intelligence, a leading news, data, and information service for the global pharmaceutical industry, on November 4, 2010 in London, England.

From Parexel 15 Nov 2010

Best ways for proper disposal of unused medicines

Patients in cities all over the country will learn tomorrow about one of the best ways to avoid today's rampant prescription drug abuse – proper disposal of unused medicines.

15 Nov 2010

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.

15 Nov 2010

Selexis announces strategic agreement with Zyngenia

Selexis SA announced today a strategic agreement with Zyngenia Inc. under which Selexis will utilize its' industry-leading SURE Cell Line Development Platform to generate production cell lines for Zyngenia's lead Zybody therapeutic programs.

15 Nov 2010

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

Domainex, Sigma-Aldrich enter collaboration to study epigenetic proteins

Domainex Ltd., the Contract Research Organization committed to excellence in drug discovery, today announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics. These epigenetic proteins regulate DNA expression and can be critical to cancer and stem cell biology research. Funding from the UK Government-backed Technology Strategy Board will support this work.

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010